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Tau is a microtubule-associated protein that plays an important role in Alzheimer’s
disease and related tauopathies. Approximately one-half of all cases of Frontotemporal
dementia with parkinsonism-17 (FTDP-17) are caused by mutations in the MAPT gene.
The N279K mutation is one of the three mutations more prevalent in FTDP-17 cases.
Several studies have demonstrated that N279K Tau mutation alters alternative splicing
inducing the presence of exon 10. Tau is mainly found in the cytosol of neuronal
cells although it has also been localized within the nucleus. Here we demonstrate by
biochemical and immunohistochemistry studies in COS-7 cells, that the proportion of
mutant N279K Tau increases compared with wild-type at the cell nucleus although cell
viability is not affected. These data will provide us with a better outline of the nuclear role
of tau protein offering new clues related with this tauopathie.
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INTRODUCTION
Tau protein is composed of six different isotypes generated by alternative splicing mechanisms in
the central nervous system (CNS) of mammals. Three of these isoforms contain three copies of
the microtubule-binding domain (Tau3R) whereas the other three isotypes contain four repeats
(Tau4R). The expression of some of these Tau isoforms is developmentally regulated. Thus, mouse
isoforms lacking exon 10 (Tau3R) are found at early developmental stages whereas Tau isoforms
containing exon 10 (Tau4R) are mainly found in murine neurons at mature developmental stages
(Avila et al., 2004; Sergeant et al., 2005). In adult human brain both Tau 3R and Tau 4R are present,
although in newborn neurons such as those in the hippocampal dentate gyrus Tau 3R is the main
isoform (Bullmann et al., 2007).
Some Tau gene mutations alter proportion Tau4R/Tau3R and this alteration is pathological.
The mechanisms regulating the ratio of Tau4R/Tau3R are due to mutations altering splicing
in some frontotemporal dementia patients present in exon 10 or intron regions flaking that
exon, mainly close to the 5′ splice site of exon 10. N279K mutation (SNP ID number:
rs63750756) present in exon 10 is extremely rare among healthy individuals, but it is
among most frequent causes of familial frontotemporal dementia1. At molecular level, N279K
mutation affects exon 10 splicing allowing exon 10 to be incorporated more frequently and
1https://www.alzforum.org/mutation/mapt-n279k
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causing an increase of Tau4R isoforms (Delisle et al., 1999;
Dawson et al., 2007). The N279K mutation strengthens
a poly-purine positive cis-element present within exon 10,
resulting in increased exon 10 inclusion during splicing process
(Hutton, 2001). Consequences of that alteration in Tau 4R/3R
proportion is the disruption of subcellular vesicle trafficking and
induction of cellular stress at least in iPSC-derived neural stem
cells (Wren et al., 2015).
Tau has mainly an axonal localization and can be found
associated with microtubules although that interaction is
highly dynamic explaining why tau can also be present in
other cellular compartments (Janning et al., 2014). Thus, Tau
can be also associated with the plasma membrane (Brandt
et al., 1995) in an interaction that could be modulated
by Tau phosphorylation (Arrasate et al., 2000; Gauthier-
Kemper et al., 2018). Also, the presence of a nuclear antigen
reacting with several Tau antibodies has been reported,
mainly in proliferating cells, demonstrating that Tau is also
a nuclear protein (for a review see Bukar Maina et al.,
2016).
Nuclear location studies seems to confer Tau an
important role in nucleolar structure conformation and
heterochromatinization of ribosomal genes (Sjöberg et al.,
2006; Rossi et al., 2008). The role that it might play in the
nucleus and the physiological consequences derived from its
interaction with DNA remains to be elucidated. However,
a function related to protection of genomic integrity has
been recently suggested to Tau protein (Sjöberg et al.,
2006). Interestingly, Tau binding to DNA is modulated
by phosphorylation (Camero et al., 2014). However, it is
unknown how Tau protein is transported to nucleus as not
clear import or export sequences has been described in Tau
protein.
Here, we explored the nuclear localization of N279K isoform
in order to know the effect of that mutation in nuclear
localization. Our data demonstrate that the proportion of
mutated Tau, at the cell nucleus, increases compared with wild-
type. The consequences of that distribution are discussed.
MATERIALS AND METHODS
Antibodies
List of antibodies used are shown in Table 1. The antibodies
against Tau used in this study were: Tau 12 (N-terminal, mouse
monoclonal); Tau 46 (C-terminal, mouse monoclonal); Tau 1
(unphosphatase-sensitive epitope corresponding to Ser199/202,
mousemonoclonal); 7.51 (againstmicrotubule-binding domain);
AD2 (Tau phosphorylated at S396/S404, mouse monoclonal);
AT-8 (Tau phosphorylated at S202, mouse monoclonal).
The monoclonal antibody directed against β-actin (Sigma
St. Louis, MO, USA) was used as internal control for protein
quantification. Anti-GADPH (Abcam) and anti-Lamin B1 (Santa
Cruz Biotechnology) were used as internal control for nuclear
extracts.
Materials
The anti-proteases cocktail and Leptomycin B and the rest of the
reagents were purchased from Sigma-Aldrich.
Tau Expression Constructs
The largest CNS isoform of wild-type human Tau
was expressed from the SV40 early promoter using
the plasmid pSGT42 previously described (Montejo de
Garcini et al., 1994). To engineer the N279K mutation,
mutagenesis was carried out using the polymerase
chain reaction (PCR) with primer N279K forward
5′-GTGCAGATAATTAAGAAGAAGCTGG-3′ and primer
N279K reverse 5′-CCAGCTTCTTCTTAATTATCTGCAC-3′
which include the mutated codon. The fragment
generated by PCR amplification on pSGT42 using
primers described above was digested with BglII and
EcoRI and ligated into the eukaryotic expression vector
pSG5 (Stratagene) under the control of SV40 early
promoter digested with the same enzymes to obtain
pSGTN279K.
Positive clones were analyzed by restriction analysis to test
for the proper orientation and correct size of the inserts. Finally,
TABLE 1 | List of antibodies.
Antibody Epitope Source, host species, catalog/clone/lot No., Dilution
Tau 12 Aminoacids 6–18 of human tau Abcam; Mouse monoclonal; Cat# ab74137 1/500 (WB)
Tau 46 Aminoacids 404–441 of human tau Abcam; human; Mouse monoclonal; Cat. #: ab22261 1/1000 (WB)
Tau 1 Unphosphorylated tau in amino acids
198–206
Calbiochem San Diego, CA, USA; Mouse monoclonal 1/5000 (WB); 1/500 (IF)
Tau 5 Amino acids 210–241 of bovine Tau Abcam; Mouse monoclonal; Cat# ab80579 1/1000
7.51 The microtubule-binding region Kindly provided by Dr. C. M. Wischik, Aberdeen, UK; Mouse monoclonal 1/100 (WB)
AD2 Phospho tau in S396/404 Biorad Laboratories; Mouse monoclonal; Cat# 56484 1/1000 (WB)
AT8 Phospho tau in S202 Innogenetics. Cat #90206 1/1000 (WB)
Anti-ERK1 C-terminus
de ERK 1
Rabbit polyclonal: Santa Cruz Biotechnology; Cat# (C-16): sc-93 1/100 (IF)
Anti-β Actin Slightly modified β-cytoplasmic actin
N-terminal peptide, Ac-Asp-Asp-Asp-
Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-
Ser-Gly-Lys, conjugated to KLH.
Sigma-Aldrich; Monoclonal; Cat# A5441 1/5000 (WB)
Anti-GADPH Rabbit muscle GAPDH Abcam; Monoclonal; Cat# AB8245 1/3000 (WB)
Anti-laminin B1 A monoclonal antibody against the
C-terminal of Laminin B1
Santa Cruz Biotechnology; Mouse monoclonal; Cat# sc-377000 1/100 (WB)
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FIGURE 1 | Maps of Tau constructs used in this work.
the constructions were confirmed by DNA- sequencing analysis.
Figure 1 shows the maps of Tau constructs used in this work.
Cell Culture and DNA Transfection
African green monkey kidney fibroblasts (COS-7) cells
(Gluzman, 1981) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% (vol/vol) fetal bovine serum
(FBS). Cells were transfected with the cDNA constructs using
PEI reagent (Polysciences, Inc) according to the manufacturer’s
instructions. The empty vector pSG5 was used to transfect
control cells.
Leptomycin B Treatment
One hour before the end of transfection, COS-7 cells were
incubated in FBS-free DMEM containing vehicle (methanol) or
20 ng/ml Leptomycin B1.
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Toxicity Assays
Cell death was assayed by using the LIVE/DEAD
viability/cytotoxicity kit (Invitrogen, Carlsbad, CA, USA) to
label live cells and ethidium homodimer-1 to label dead cells.
1 × 105 COS-7 cells were seeded to each well of a 24-well
plate and transfected with the plasmids described above.
After 48 h postransfection, cell viability was measured using
LIVE/DEAD viability kit. Cells were incubated for 20 min with
2 µM propidium iodide and 1 µM calcein. After staining, live
cells (green) and dead cells (red) were visualized on a Leica
fluorescence microscope and images were taken. Three fields
(selected at random) were analyzed per well (100–500 cells/field)
and counted with ImageJ software. Cell viability was defined in
each condition as the percentage of live cells vs. the total number
of cells.
Western Blotting
At 48 h post-transfection, cells were homogenized in lysis buffer
(20 mM HEPES pH 7.4, 5 mM EDTA, 100 mM NaCl, 1%
Triton X-100, 0.1 mM sodium orthovanadate, protease inhibitor
cocktail and 0.1 µMOkadaic acid). Lysates were centrifugated at
10,000 g for 15 min at 4◦C and protein samples were quantified
by the BCA protein assay. Samples were separated on 10%
SDS-PAGE and electrophoretically transferred to a nitrocellulose
membrane (Schleicher & Schuell GmbH). The membrane was
blocked by incubation with 5% semi-fat dried milk in PBS and
0.1% Tween 20 (PBSM), followed by 1-h incubation at room
temperature with the primary antibody in PBSM. The following
primary antibody dilutions were used: T12 (1/500); T46 (1/1000);
Tau5 (1/1000): Tau 1 (1/5000); 7.51 (1/100); AD2 (1/500);
anti-GADPH (1/3000); anti-Lamin B1 (1/250) and anti-β actin
(1/5000). After three washes, the membrane was incubated
with a horseradish peroxidase-anti-mouse Ig conjugate (DAKO),
followed by several washes in PBS-Tween 20. The membrane
was then incubated for 1 min in Western Lightning reagents
(PerkinElmer Life Sciences).
Blots were quantified using the EPSON Perfection
1660 scanner and the ImageJ1.46r image analysis system.
The levels of various markers were normalized to the β-actin
present in each band.
Nuclear Extracts
Adherent cells were washed with ice-cold PBS and scraped into
ice-cold hypotonic Buffer A (20 mM HEPES pH 7, 0.15 mM
EDTA, 0.015 mM EGTA, 10 mM KCl, 1% NP-40 supplemented
with protease inhibitors), incubated for 30 min on ice in a
rotating wheel and pelleted by centrifugation at 2300 rpm for
5 min at 4◦C. Supernatant was collected as cytosolic fraction.
Nuclear pellet was washed in five volumes of buffer B (10 mM
HEPES pH 8, 25% (v/v) Glycerol, 0.1 M NaCl and 0.15 mM
EDTA). After centrifugation as above, nuclei in the pellet were
resuspended in two cellular volumes of Buffer A.
Immunofluorescence and Confocal
Microscopy
For immunofluorescence studies, cells were fixed with 4%
formaldehyde. Subsequently, the fixed cells were permeabilized
FIGURE 2 | Cell viability of COS-7 cells. Cell viability under control conditions,
transfected with empty pSG5 or with pSG5-Tau 42 or with pSG-Tau N279K
was measured by labeling with calcein-AM (live cells) and ethidium
homodimer-1 (dead cells), 48 h after transfection. Quantification of the
percentage of live cells in each condition is shown.
with 0.1% Triton X-100 and Glycine 1 M for 30 min. After
fixation, the coverslips were blocked with 1% bovine serum
albumin for 30 min and subsequently incubated with primary
antibodies in PBS containing 1% bovine serum albumin
for 1 h. Coverslips were rinsed three times with PBS and
incubated 45 min with Alexa 488-conjugated anti-mouse
(diluted 1:400; Thermo Fisher). All the coverslips were
finally counterstained for 3 min with 4′,6-Diamidine-2′-
phenylindole dihydrochloride (DAPI; 1:1000, Calbiochem-EMD
Darmstadt, Germany). After washing with PBS, the coverslips
were mounted with FluorosaveTM (Calbiochem, San
Diego, CA, USA). Confocal images were obtained using
a TCS SP5 Spectral Leica Confocal microscope using an
oil-immersion 40× objective with sequential-acquisition
setting. The detector pinholes were set to give a 0.3 µm optical
slice.
Data Analysis
Data are presented as the mean ± SD. Two group comparisons
were made using unpaired Student’s two-tailed t-test.
Significance was accepted at p< 0.05.
RESULTS
Overexpression of Tau Without Cell Death
To determine if overexpression of plasmids used in this work
was or not toxic for the cells, we performed a toxicity assay.
Figure 2 shows that cell viability under control conditions,
transfected with empty pSG5 or with pSG5-Tau 42 or with
pSG-Tau N279K plasmid did not correlated with cell death,
given the low rate of cell death observed in the cultures of
transfected COS-7.
Effect of the N279K Mutation on Tau
Phosphorylation in COS-7 Cells
The human wild-type Tau 42 and mutant Tau N279K
(Figure 3A) plasmids were transfected into COS-7 cells
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FIGURE 3 | Analysis of human Tau 42 and Tau N279K mutant in COS-7 cells. (A) Human Tau 250–300 sequence showing mutated amino acid N279K in red.
(B) Schematic representation of Tau 42 (T42) correspond to the longest human cDNA isoform of the protein (Goedert et al., 1989). Gray squares indicate the
29-amino acid inserts close to the N-terminal end. Striped square indicates the tubulin binding repeats. Epitopes of antibodies used are indicated. (C) Wild-type Tau
(Tau 42) and mutant Tau (Tau N279K) were transfected in COS-7 cells. Forty-eight hours after transfection, cell lysates were obtained and analyzed by Western-blot
using several anti-Tau antibodies. Actin amount was used in each case as protein loading control. To analyze phosphorylation at AT8 epitope, cells were incubated
during 1 h with okadaic acid (0.5 µM). Quantification of AT8 and AD2 antibodies are shown using 7.51 antibody to measure total unphosphorylated tau.
AD2 quantification did not show a significant difference, although a tendency toward increase was found. Data are mean ± SD from four separate experiments
(∗p < 0.05).
to explore the effect of the N279K mutation on Tau
phosphorylation. The level of Tau was determined by
measuring the reactivity of the protein with the monoclonal
antibodies T12, T46, 7.51 and Tau 1, which recognize Tau
independently of its modification state, and AT8 and AD2,
which recognizes phosphoserine 202 and phosphoserines
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FIGURE 4 | Localization of Tau in COS-7 cells transfected with empty plasmid pSG5, human Tau 42 or Tau N279K. Representative images of localization of Tau
42 and Tau N279K using anti-Tau 1 antibody (green). The localization of nucleus was determined by immunofluorescence with 4′,6-Diamidine-2′-phenylindole
dihydrochloride (DAPI). Bar indicates 50 µm. Arrows show nuclear localization of transfected Tau.
396/404 respectively (Buée-Scherrer et al., 1996; Figure 3B).
AT8 antibody did not recognize phosphorylated human
wild-type Tau 42 or mutant Tau N279K (data not shown).
However, when transfected cells were incubated during 1 h
with okadaic acid (0.5 µM) an increase in phosphorylated
tau could be observed. Figure 3C shows an increase in the
level of phosphorylation at AT-8 epitope of the N279K
mutated Tau protein compared with that of wild-type Tau.
AD2 signal did not increase at significant levels although
an increasing trend was observed. In vitro studies have
shown that the N279K mutation does not alter the binding
of Tau to MTs or decrease the ability of Tau to promote
MT assembly (Hong et al., 1998; Barghorn et al., 2000), our
results would suggest that phosphorylation of Tau N279K
at AT8 epitope could bind to microtubules worse than
wild-type Tau.
Effect of the N279K Mutation on Nuclear
Localization of Tau in COS-7 Cells
Many studies have indicated that Tau is present in both
the cytoplasmic and nuclear compartments (see review
Bukar Maina et al., 2016). To analyze the subcellular
distribution of Tau N279K, we first performed analysis by
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FIGURE 5 | Analysis of Tau localization by Western-blot. (A) Representative
Western-blot analysis using unphospho-dependent Tau antibody Tau 1 and
Tau5. COS-7 cells transfected with both Tau constructs and empty plasmid
were subjected to cellular fractionation as described in “Materials and
Methods” section. Distribution of Tau was analyzed in cytosolic (Cyto) and
nuclear (nucleus) fractions. GADPH and Lamin B were respectively used as
specific markers of the cytoplasmic and the nuclear fractions. (B)
Quantification of ratio Nucleus/Cytoplasm of Tau-1 signal is the mean ± SD
(n = 4, ∗p < 0.05).
confocal microscopy for cytoplasmic or nuclear localization
of Tau constructs. While Tau 42 showed a preferential
cytoplasmic localization, Tau N279K was present in both
the cytoplasm and the nucleus (Figure 4). To confirm
these data obtained by immunofluorescence, we performed
subcellular fractionation (see ‘‘Materials and Methods’’
section) on transient transfected COS-7 cells with both
plasmids and then analyzed by Western blot analysis
with Tau1 antibody (Figure 5A). We used anti-GADPH
antibody as a cytoplasm marker antibody and the anti-Lamin
B1 antibody as a nuclear marker antibody. Tau 42 can be
found in the cytosol compartment as well as in the nuclear
compartment. This was in agreement with previous results
obtained in human neuroblastoma cells (Loomis et al.,
1990). Also, we detected Tau N279K in either cytosol as
in nucleus fraction, being the levels of Tau N279K in the
nucleus slight greater than Tau 42 (approximately it was
increased up to 1.5-fold, Figure 5B). This result would
suggest a role of N279K in subcellular localization of Tau
in COS-7 cells.
To confirm that the mutation N279K localizes in the
nuclear compartment, we treated COS-7 cells with Leptomycin
an inhibitor of nuclear export that blocks the transport of
the nuclear export signals (NES)-containing protein from
the nucleus to the cytoplasm (Kudo et al., 1998). COS-7
cells were transfected with each of the constructs and
cytoplasmic–nuclear Tau localization was analyzed by Western
blot (Figure 6A). The accumulation of both Tau 42 and
Tau N279K was approximately increased up to 2-fold in the
nucleus of COS-7 cells after cell treatment with Leptomycin B
(Figure 4B). Furthermore, transfection of mutant Tau into the
cells resulted in a greater nuclear localization respect Tau 42
(Figure 6B).
Taken together, data presented in this work suggest that the
Tau mutation N279K alters distribution between the cytosol and
the nucleus and likely contribute to neurodegeneration.
DISCUSSION
Tau residue N279 has been extensively studied. Thus, this
asparagine can be modified by deamination in Alzheimer disease
samples (Dan et al., 2013) and it may favor Tau aggregation
(Montejo de Garcini et al., 1986). Asparagine-279 can be
mutated to lysine causing one of the most frequent causes
of familial frontotemporal dementia. That mutation increases
Tau4R/Tau3R ratio by altering alternative splicing of exon 10
(Delisle et al., 1999), but has not effects on Tau binding to
microtubules or the ability of Tau to promote MT assembly
(Hong et al., 1998). In this work, we have analyzed the
consequences of that mutation on the subcellular localization of
Tau protein.
Our results demonstrate by biochemical and
immunohistochemistry studies that N279K mutation alters
distribution between the cytosol and the nucleus. We have
found that human Tau bearing the mutation N279K is located,
in higher proportion than wild-type Tau, at the cell nucleus.
Taking into account this, and that NES are domains rich in
leucines, we observed that two leucines are found in position
282 and 284. Thus, we wonder if there exist a nuclear export
sequence around that epitope. Bioinformatic analysis of all
Tau sequence using the neuronal network/hidden Markow
model-based prediction method NetNES2 (la Cour et al., 2004)
predicts a NES between residues 277 and 284 in the case
of mutant protein. The calculated ‘‘NES score’’ exceeds the
threshold between residues 277 and 284 (IIKKKLDL) while
wild-type sequence (IINKKLDL) the threshold is only exceeded
by the L284 suggesting that N279K mutation participates in
generate a stronger nuclear export signal. Interestingly all
the sequence is present in exon 10 confirming experimental
data suggesting that Tau4R isoforms are found in the nucleus
(Liu and Götz, 2013). However, while in silico data propose
that N279K mutation creates a stronger NES in exon 10,
2http://www.cbs.dtu.dk/services/NetNES/
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FIGURE 6 | Treatment of cells with an inhibitor of nuclear export, LMB, causes retention of Tau in the nucleus. (A) COS-7 cells transfected with empty plasmid, Tau
42 or Tau N279K were incubated with LMB for 1 h. Distribution of Tau was analyzed in cytosolic (Cyto) and nuclear (nucleus) fractions by Western-blot using Tau
1 antibody. GADPH and Lamin B were respectively used as specific markers of the cytoplasmic and the nuclear fractions. (B) Quantification of the nucleus intensity
of Tau 42 and Tau N279K are shown. Data are mean ± SD (n = 3; ∗∗p < 0.01).
our biochemical data suggested that this is not the case. In
fact, overexpression of mutant Tau results in the opposite,
an increase in the proportion of mutant Tau presents in the
nucleus. In any case, further investigations are necessary in
order to know if the export/import nuclear machinery and
Tau phosphorylation present in COS-7 cells are different
compared with neuronal cells or if the system is saturated
in overexpressing cells. It should be taken into account
that, as has been recently published (Eftekharzadeh et al.,
2017), phosphorylated Tau may disrupt nucleocytoplasmic
transport through the binding of phosphoTau to nuclear pore
machinery.
We here also show that one of the characteristics of N279K
Tau is that is highly phosphorylated compared with wild-type
Tau as determined by its interaction with antibody AT8 and
AD2. The result of that phosphorylation could be a dysfunction
at the nuclear pore, this together with the fact that cytoplasmic
aggregates can disrupt nucleocytoplasmic transport of proteins
and RNAs (Woerner et al., 2016) could explain to some extent the
toxicity of N287K Tau. An additional explanation to the results
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obtained would be that taking into account that phosphorylated
Tau binds less to microtubules than the unphosphorylated Tau,
it is possible that more Tau would be available for redistributing
into the nuclear compartment.
It is also possible that other Tau domains could be involved
in nuclear Tau localization. Thus, in the adult murine brain,
Tau mainly have four microtubule-binding repeats and the
presence of only one amino-terminal inserts in the 4R isoform
are localized in the nucleus while those 4R isoforms with 0 or
1 amino-terminal inserts N-terminal are hardly localized in the
nucleus (Liu and Götz, 2013).
In summary, we like to support the role of exon 10 (Tau 4R)
for the presence of Tau at the cell nucleus, a role that could be
facilitate by the presence of N279K Tau mutation.
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